secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2022-09-08T23:59:59+00:00
Accession:  0001193125-22-240991
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Homology Medicines appoints Albert Seymour as CEO; Arthur Tzianabos named Chairman
--------------------------------------------------------------------------------

- Albert Seymour, former CSO and President, promoted to CEO; base salary raised to $570,000, bonus target 55%.
- Seymour received option for 23,000 shares at $2.18 and 14,000 RSUs, vesting over 48 months and 3 years.
- Arthur Tzianabos resigned as CEO, appointed Chairman of Board; consulting agreement pays $26,571/month through March 31, 2023.
- Kush Parmar resigned from Board and Chairman role; Jeffrey Poulton appointed Lead Director.
- CFO W. Bradford Smith's severance amended: 12 months base salary continuation on qualifying termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000119312522240991/0001193125-22-240991-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000119312522240991/d403635d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-240991

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer